Table 1 Clinical characteristics and comparison between with and without BC infections in HSCT patients
Characteristic | Total | With BC (n = 32) | Without BC (n = 32) | P-value |
|---|---|---|---|---|
Age, years (mean ± SD) | 19.16 ± 15.31 | 19.62 ± 16.33 | 18.69 ± 14.47 | 0.809 |
Gender, n (%) | Â | Â | Â | 0.274 |
 Male, n (%) | 45 (70.3) | 25 (78.1) | 20 (62.5) |  |
 Female, n (%) | 19 (29.7) | 7 (21.9) | 12 (37.5) |  |
Primary disease, n (%) | Â | Â | Â | 1.000 |
 Acute myelogenous leukemia | 16 (25) | 8 (25) | 8 (25) |  |
 Thalassemia | 36 (56.2) | 18 (56.2) | 18 (56.2) |  |
 Chronic myelogenous leukemia | 12 (18.8) | 6 (18.8) | 6 (18.8) |  |
Infection site, n (%) | Â | 0.781 | ||
 Pulmonary infection | 46 (71.9) | 24 (75) | 22 (68.8) |  |
 Bloodstream infection | 18 (28.1) | 8 (25) | 10 (31.2) |  |
aGVHD, n (%) | 55 (85.9) | 25 (78.1) | 30 (93.8) | 0.148 |
Catheter, n (%) | 4 (6.2) | 2 (6.2) | 2 (6.2) | 1.000 |
Indicators of initial stage of infection | Â | |||
 Neutrophil count < 0.5 × 109/L, n (%) | 14 (21.9) | 4 (12.5) | 10 (31.2) | 0.131 |
 Platelet count < 20 × 109/L, n (%) | 16 (25) | 4 (12.5) | 12 (37.5) | 0.043* |
 Creatinine > 177 µmol/L, n (%) | 6 (9.4) | 6 (18.8) | 0 (0) | 0.024* |
 Total bilirubin > 34.2 µmol/L, n (%) | 14 (21.9) | 6 (18.8) | 8 (25) | 0.762 |
Hematopoietic engraftment, days (mean ± SD) | 18.5 ± 8.53 | 19.97 ± 10.3 | 17.03 ± 6.12 | 0.17 |
Multiple site/pathogen infection after transplantation, n (%) | 22 (34.4) | 16 (50) | 6 (18.8) | 0.018* |
Use of anti-CMV immunoglobulin after transplantation, n (%) | 24 (37.5) | 20 (62.5) | 4 (12.5) | < 0.001* |
Admission to ICU after transplantation, n (%) | 26 (40.6) | 20 (62.5) | 6 (18.8) | < 0.001* |
Mechanical ventilation, n (%) | 17 (26.6) | 11 (34.4) | 6 (18.8) | 0.258 |
Septic shock, n (%) | 18 (28.1) | 14 (43.8) | 4 (12.5) | 0.012* |
Mortality, n (%) | 26 (40.6) | 18 (56.2) | 8 (25.0) | 0.022* |